Loading
Angiogenesis and VEGF in Cancer / Pulmonary Hypertension Research and Treatments · Review
Egyptian Journal of Bronchology · August 8, 2026
Raises a question worth testing. It does not answer one.
This narrative review examines the role of VEGFR signalling in hemoptysis, finding that while VEGFR-2 inhibitors are biologically plausible candidates, the current evidence is limited to case reports and small retrospective studies, with no controlled trial evidence. Critically, the review identifies a central paradox: VEGFR-2 inhibition may reduce bleeding through vascular normalisation but may also precipitate fatal pulmonary haemorrhage through tumour necrosis in centrally located or cavitating tumours.
Narrative review. Literature on hemoptysis aetiology, VEGFR biology, and VEGFR inhibitor use in lung cancer and infective/inflammatory disease; patients with hemoptysis from lung cancer, bronchiectasis, tuberculosis, and pulmonary disease.. Intervention: VEGFR-2 inhibitors (apatinib, anlotinib) and VEGFR signalling biology..
In approximately 90% of hemoptysis cases, bleeding arises from the high-pressure bronchial arterial circulation rather than the low-pressure pulmonary circulation. Dominant mechanisms of hemoptysis (bronchial artery hypertrophy, systemic neovascularisation, cavitary wall erosion, Rasmussen aneurysm, direct tumour invasion) are not primarily driven by VEGFR signalling. Evidence for VEGFR-2 inhibitors (apatinib, anlotinib) is confined to case reports, small retrospective series, and oncology trials in which bleeding was recorded as an adverse event rather than efficacy endpoint.
Central paradox unresolved: mechanism by which VEGFR-2 inhibition might reduce bleeding (vascular normalisation) is opposed by risk of fatal haemorrhage (tumour necrosis); no prospective data on relative frequency or predictors. In approximately 90% of hemoptysis cases, bleeding arises from the high-pressure bronchial arterial circulation rather than the low-pressure pulmonary circulation.
Clinicians should recognise that VEGFR-targeted therapy remains experimentally unproven for hemoptysis treatment and is not an alternative to airway stabilisation, bronchial artery embolisation, bronchoscopy, or surgery. Any use should be restricted to carefully selected patients within a prospective validation framework, with explicit attention to tumour phenotype (cavitating, centrally located, or vessel-abutting lesions carry heightened necrosis risk).
A narrative review synthesizing mechanistic biology and case evidence that identifies a biologically plausible but clinically unproven hypothesis about VEGFR inhibition in hemoptysis, explicitly noting absence of controlled trials and the paradoxical risk of fatal hemorrhage.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognise that VEGFR-targeted therapy remains experimentally unproven for hemoptysis treatment and is not an alternative to airway stabilisation, bronchial artery embolisation, bronchoscopy, or surgery. Any use should be restricted to carefully selected patients within a prospective validation framework, with explicit attention to tumour phenotype (cavitating, centrally located, or vessel-abutting lesions carry heightened necrosis risk).
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Hemoptysis is a potentially life-threatening manifestation of pulmonary disease, including lung cancer, bronchiectasis and pulmonary tuberculosis. Critically, in approximately 90% of cases the bleeding arises from the high-pressure bronchial (systemic) arterial circulation rather than from the low-pressure pulmonary circulation, and the dominant mechanisms — bronchial artery hypertrophy and systemic neovascularisation, cavitary wall erosion, Rasmussen aneurysm and direct tumour invasion of vessels — are not primarily driven by vascular endothelial growth factor receptor (VEGFR) signalling. VEGFR signalling nevertheless regulates angiogenesis and vascular permeability, is upregulated in lung cancer and in infective and inflammatory lung disease, and is the target of agents that are increasingly used in patients who bleed. This narrative review therefore asks a deliberately restricted question: what can, and what cannot, VEGFR biology explain about hemoptysis? We describe the review methodology, separate neoplastic from infective and inflammatory aetiologies rather than treating VEGFR as a common driver, and grade the supporting evidence explicitly. We find that the evidence for VEGFR-2 inhibitors (apatinib, anlotinib) as a treatment for hemoptysis is confined to case reports, small retrospective series, and oncology trials in which bleeding was recorded as an adverse event rather than an efficacy endpoint; no controlled trial has evaluated a VEGFR inhibitor for the treatment of hemoptysis, and pivotal trials systematically excluded patients with major vascular invasion or significant hemoptysis. We give particular attention to the central paradox of the field: VEGFR-2 inhibition may reduce bleeding through vascular normalisation, yet in centrally located, cavitating or vessel-abutting tumours the same on-target activity precipitates tumour necrosis and fatal pulmonary haemorrhage. We propose an explicit phenotype-based framework separating patients in whom normalisation plausibly dominates from those in whom necrosis dominates. VEGFR-targeted therapy is not an alternative to airway stabilisation, CT angiography, bronchoscopy, bronchial artery embolisation, surgery and treatment of the underlying disease, and should be positioned only as a disease-directed adjunct in carefully selected patients. Taken together, current evidence supports a biologically plausible but clinically unproven role for VEGFR-targeted therapy in carefully selected patients, which requires prospective validation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.